Hamad, Jimer A.
HRN: 21-75-40 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/21/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
12/21/2022
12/27/2022
IV
120mg
Q24Hrs
PCAP-D
Waiting Final Action
Indication: Empiric Type of Infection: PneumoniaBloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes